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The function of natural killer (NK) cells is controlled by several activating and inhibitory
receptors, including the family of killer-immunoglobulin-like receptors (KIRs). One distinc-
tive feature of KIRs is the extensive number of various haplotypes generated by the gene
content within the KIR gene locus as well as by highly polymorphic members of the KIR
gene family, namely KIR3DL1/S1.Within the KIR3DL1/S1 gene locus, KIR3DS1 represents
a conserved allelic variant and displays other unique features in comparison to the highly
polymorphic KIR3DL1 allele. KIR3DS1 is present in all human populations and belongs
to the KIR haplotype group B. KIR3DS1 encodes for an activating receptor featuring the
characteristic short cytoplasmic tail and a positively charged residue within the transmem-
brane domain, which allows recruitment of the ITAM-bearing adaptor molecule DAP12.
Although HLA class I molecules are thought to represent natural KIR ligands, and HLA-Bw4
molecules serve as ligands for KIR3DL1, the ligand for KIR3DS1 still needs to be identi-
ﬁed. Despite the lack of formal evidence for an interaction of KIR3DS1 with HLA-Bw4-I80
or any other HLA class I subtype to date, a growing number of associations between the
presence of KIR3DS1 and the outcome of viral infections have been described. Especially,
the potential protective role of KIR3DS1 in combination with HLA-Bw4-I80 in the context
of HIV-1 infection has been studied intensively. In addition, a number of recent studies
have associated the presence or absence of KIR3DS1 with the occurrence and outcome of
some malignancies, autoimmune diseases, and graft-versus-host disease (GVHD). In this
review, we summarize the present knowledge regarding the characteristics of KIRD3S1
and discuss its role in various human diseases.
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INTRODUCTION
Killer-immunoglobulin(Ig)-likereceptors(KIRs)representafam-
ilyofactivatingandinhibitoryreceptorsexpressedonnaturalkiller
(NK)cellsthatshapeandregulateNKcellfunctions(Morettaetal.,
1993). All human KIRs share common structural features includ-
ing a cytoplasmic domain, a transmembrane domain and either
two or three Ig-like extracellular domains (D0,D1,and D2). Each
of these structural domains has a functional role with regards
to ligand speciﬁcity and signal transduction after engagement
of the respective receptor. Based on the number of extracellu-
lar domains, KIR proteins are classiﬁed as KIR2D (two domains)
and KIR3D (three domains) receptors. KIR2D receptors can be
further subdivided into a type I and type II group depending
on the characteristics of the two extracellular domains. Type I
KIR2D proteins, such as KIR2DL1-3 and KIR2DS1-5, exhibit a
D2 and D1 domain. In contrast, KIR2DL4 and KIR2DL5 encode
for type II KIR2D proteins lacking the D1 domain but comprising
a D0 domain similar to the membrane-distal domain of KIR3D
proteins.
The intracellular domains of KIRs feature either a short or a
long cytoplasmic tail (S or L in the nomenclature, respectively).
The long cytoplasmic tail contains two immune tyrosine-based
inhibitory motifs (ITIM) which lead to the transduction of an
inhibitorysignalandthusdeﬁnesinhibitoryKIRs.Incontrast,KIR
genes encoding for activating receptors possess short cytoplasmic
tails, which have a positively charged amino acid residue in their
transmembrane region. This allows recruitment of the DAP12
adaptor molecule that contains an immunoreceptor tyrosine-
based activating motif (ITAM) and transmits an activating signal.
An exception is KIR2DL4, which contains only one ITIM within
the long cytoplasmic tail and additionally possesses a charged
residue, thus, making it capable of triggering both inhibitory and
activating signals (Faure and Long, 2002).
Within the 14 described human KIRs, KIR3DS1 displays sev-
eral unique features compared, in particular, to its inhibitory
counterpart KIR3DL1. KIR3DS1 represents the only activating
receptor with three extracellular domains. Moreover, in con-
trast to the highly polymorphic KIR3DL1, KIR3DS1 is almost
monomorphic (Norman etal., 2007; Parham etal., 2011). The
interactions between KIR3DL1 and its natural ligands, HLA class
I molecules of the HLA-Bw4 family have been studied inten-
sively and conﬁrmed by crystal structures (Vivian etal., 2011).
In contrast, the natural ligand of KIR3DS1 has yet to be iden-
tiﬁed. Recent genetic and functional studies have suggested that
certain HLA-Bw4 molecules containing an isoleucine in position
80 (HLA-Bw4-I80) are a potential putative ligand for KIR3DS1
(Martin etal., 2002; Alter etal., 2007, 2009). However, despite
several attempts by different groups, direct interactions between
KIR3DS1 and HLA-Bw4 molecules have not yet been demon-
strated (Carr etal., 2007; Gillespie etal., 2007; O’Connor etal.,
2007),with the exception of one report by Li etal. (2010) suggest-
inginteractionsbetweenKIR3DS1andtheHLA-Bw4-T80allotype
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HLA-B*2705.However,thestudyitselfdisplayedsomelimitations,
which include the lack of adequate negative controls to prove that
binding of KIR3DS1 to the HLA/peptide complex was speciﬁc.
Nevertheless,severalstudieshaveobservedsigniﬁcantassociations
betweenthepresenceof KIR3DS1andtheoutcomeof humandis-
ease, suggesting an undiscovered role of KIR3DS1 in modulating
NK cell function (Martin etal., 2002; Lopez-Vazquez etal., 2005;
Gabriel etal.,2010).
EVOLUTION AND GENETICS
In humans, KIR3DL1/S1 is clustered with other genes of the KIR
family within a 100–200 kb region of the leukocyte receptor com-
plex (LRC) on chromosome 19 (19q13.4; Trowsdale, 2001). The
KIR locus can be divided into a centromeric and a telomeric
part, which are ﬂanked by so called framework genes (Wilson
etal., 2000). The centromeric region is conﬁned by KIR3DL3 and
KIR3DP1, while the telomeric region of the KIR gene locus is
enclosed by KIR2DL4 and KIR3DL2. Within the region between
these framework genes, the numbers and types of KIRs present
within a given individual are highly variable resulting in extensive
numbers of different haplotypes. The current KIR genes and the
resulting haplotypes display a snapshot of the rapid evolution of
the KIR gene locus that is driven by selection. The close proxim-
ity of the KIR genes within the centromeric and telomeric region
and the organization of the KIR locus in a head-to-tail fashion
probably facilitated gene expansion by duplication and recombi-
nation, and is reﬂected by the substantial linkage disequilibrium
between KIRs (Gourraud etal.,2010),e.g.,between KIR3DS1 and
KIR2DS1(Hollenbachetal.,2010).Inaddition,unequalcrossover
and generation of extended KIR haplotypes with multiple copies
of an individual gene have been described for KIR3DL1/S1 and
KIR2DL4 (Martin etal.,2003;Williams etal.,2003).
KIRhaplotypescanbegenerallydistinguishedintotwogroups,
AandB,whichnotonlyreﬂectdifferencesintheirgenecontentand
allelicvariabilitybutalsotheircontributiontothesusceptibilityof
variousdiseases(Uhrbergetal.,1997;Hsuetal.,2002;Marshetal.,
2003). Individuals encoding the KIR3DS1 gene are considered to
have the KIR haplotype B, which is deﬁned by the presence of at
least one of the following genes: KIR2DL5, KIR2DS1, KIR2DS2,
KIR2DS3, KIR2DS5, and KIR3DS1. Haplotype A is deﬁned by the
absenceoftheabovegenes,respectively.IncontrasttotheKIRhap-
lotype A, in which genetic variability is created by a broad allelic
variance within each KIR gene, variability within B haplotypes is
achieved by the presence or absence of most of the activating KIR
genesandKIR2DL5.Hence,allelesof activatingKIRsaccountonly
for a minority of KIR alleles (Marsh etal., 2003; Robinson etal.,
2010).Thissuggestsageneralevolutionaryconceptinwhichallelic
variance of activating KIRs is either limited by natural selection
potentially due to increased occurrence of autoimmune diseases,
orisnotrequiredbecauseof thevastpossiblecombinationsresult-
ing from gene arrangements. An alternative hypothesis is that the
limiteddiversiﬁcationofactivatingKIRssimplyreﬂectstheshorter
time period since the ﬁrst appearance of activating KIRs as com-
pared to the ancestral inhibitory KIR proteins. Nevertheless, KIR
haplotypegroupAaswellasgroupBarepresentinallhumanpop-
ulation indicating an evolutionary advantage for the maintenance
of both haplotype groups (Gendzekhadze etal., 2006,2009).
The KIR3DL1/S1 gene locus displays a unique feature of con-
taining reciprocal subsets of allotypes encoding either for the
inhibitory receptor KIR3DL1 or the activating receptor KIR3DS1
(Campbell and Purdy, 2011). While KIR3DL1 allotypes exhibit a
high rate of single nucleotide polymorphisms (SNPs),KIR3DS1 is
almost monomorphic (Norman etal., 2007; Parham etal., 2011).
As a consequence, most of the approximately 70 known allotypes
of KIR3DL1/S1 account for KIR3DL1. Because of its opposing
functional characteristic in comparison to KIR3DL1, KIR3DS1
was initially considered to be the product of a discrete gene
(Valianteetal.,1997). However,furthersegregationstudiesidenti-
ﬁed KIR3DS1 as a functional allele of the KIR3DL1/S1 gene locus
(Marsh etal., 2003; Traherne etal., 2010).
The evolutionary history of KIR3DL1/S1 can be traced back
beforetheradiationof theplacentalmammals,approximately135
million ago. The ancestral founder gene KIR3D diverged upon
gene duplication into KIR3DX and KIR3DL (Sambrook etal.,
2006; Guethlein etal., 2007). While KIR3DX remained a pseu-
dogene within the leukocyte Ig-like receptors (LILR) gene locus,
KIR3DL expanded and evolved rapidly through duplication and
recombination forming diverse lineages within simian primates.
BasedonancestralinhibitoryKIRswiththeircharacteristicITIMs
located within the long cytoplasmic tail, the appearance of KIRs
with activating properties resulted from new mutations within
the TM and the cytoplasmic tail (Abi-Rached and Parham,2005).
Elimination of ITIMs that account for the suppressive proper-
ties of inhibitory KIRs resulted from mutations or stop codons
leading to alterations of length of the cytoplasmic tail. This pro-
cess was accompanied by the introduction of a positively charged
amino acid residue within the TM allowing activating KIRs to
interact with the DAP12 adaptor molecule, which possesses an
ITAM (Lanier etal., 1998;Vivier etal., 2004).
Based on sequences as well as on the presence and frequency
of KIR3DL1/S1 allotypes in the human populations, KIR3DL1/S1
alleles can be classiﬁed into three distinct phylogenetic lineages
that evolved more than 3 million years ago: 3DL1*015-like,
3DL1*005-like, and 3DS1*013-like (Norman etal., 2007; Parham
etal., 2011). In line with this, the allotypes KIR3DL1*015,
KIR3DL1*005, and 3DS1*01301 each represent the prototypi-
cal alleles of the lineages due to their abundance in all human
populations. Although KIR3DS1*01301 is the most abundant
KIR3DL1/S1alleleworldwide,lowerallelefrequenciesof KIR3DS1
in sub-Saharan Africans have been described, indicating that nat-
ural selection for inhibitory alleles of KIR3DL1/S1 is potentially
due to increased exposure to a wide variety of pathogens over
al o n gt i m ep e r i o d( Norman etal., 2007). In this context, Abi-
Rached and Parham (2005) introduced a provocative hypothesis
that might provide an explanation for the maintenance and diver-
siﬁcation of activating KIRs as a result of balanced selection of
the KIR haplotype groups A and B (enriched for activating KIRs)
observed in modern human populations. The authors postulated
that activating KIRs undergo an initial phase of positive selection,
whichisdrivenbyanincreasedresistancetopathogensandrepro-
ductivesuccess.Thisphaseisthenfollowedbyaperiodof negative
selection that is caused by the negative effects of autoimmunity.
Although the presence and maintenance of both KIR haplotype
groups A and B in all human populations are in line with this
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hypothesis and indicate a complementary function of the KIR
haplotype groups A and B, the underlying mechanisms are still
underdiscussion.Inparticular,theepidemiologicalstudiesonKIR
and reproduction that have suggested an association of maternal
homozygosity for KIR haplotype group A with an increased risk
for pregnancy complications such as preeclampsia and recurrent
miscarriage are so far limited to KIR2D molecules (Hiby etal.,
2004,2008,2010).
REGULATION OF TRANSCRIPTION AND EXPRESSION
The expression patterns of human KIR proteins within a single
individual’s NK cell population are highly complex. They may
be affected by many factors including frequency, expression lev-
els, and co-expression of other KIRs. These determinants are
controlled by genetic and epigenetic factors some of which have
been identiﬁed over the past years, in particular for KIR3DL1/S1.
Key players in the regulation of KIR expression are the promoter
regions, which display different afﬁnities to transcription factors
due to sequence variations.
Similar to most of the KIR genes,transcription of KIR3DL1/S1
isregulatedbya∼2kbsmallregionupstreamofthecodingregion.
With the exception of KIR2DL4,the promoters within this region
are highly homologous throughout the KIR locus (Wilson etal.,
2000). The expression of the encoded KIR genes is regulated by
the degree of DNA methylation, which prevents transcription in
the early stages of NK cell development (Chan etal., 2005; San-
tourlidis etal., 2008). During maturation and education of NK
cells, the KIR expression pattern of each NK cell is thought to be
deﬁned by hypo- or hypermethylation of the distinct promoters
(Santourlidis etal., 2002; Chan etal., 2003). The level of expres-
sion of KIR3DL1/S1 is determined by a complex interplay of the
activity of two promoters within the intergenic region upstream
of KIR3DL1/S1. While the distal promoter only transcribes sense
mRNA, the proximal promoter features a bidirectional promoter
activity, producing either sense or antisense mRNA in a proba-
bilistic fashion resulting in either silenced or increased expression
of KIR3DL1/S1(Stewartetal.,2003;vanBergenetal.,2005;Davies
etal., 2007; Stulberg etal., 2007). SNPs within the proximal pro-
moters determine the activity and transcription of sense and
antisense mRNA, resulting in different expression levels and fre-
quencies of the different KIR3DL1/S1 alleles (Yawata etal., 2006;
Li etal.,2008).
However, these SNPs can only partially explain the discor-
dant observation of low transcription ratio and frequency of
KIR3DS1 in NK cells. Depending on homo- or heterozygosity of
theKIR3DS1allele,thefrequencyof NKcellsexpressingKIR3DS1
can range between ∼40–80 and 10–60% respectively (O’Connor
etal., 2007; Pascal etal., 2007). This indicates the involvement
of other factors inﬂuencing KIR3DS1 expression on NK cells.
In fact, it has been shown that surface expression of KIR3DS1
can be induced by various stimuli, such as IL-2, IL-15, or the
MHC class I deﬁcient K562 cell line (Morvan etal., 2009). More-
over,Yawata etal. (2006) observed increased numbers of NK cells
expressing KIR3DL1 and KIR2DL1 in individuals carrying the
cognate HLA ligands, indicating a possible effect of HLA ligands
on the expression of their respective KIR receptors. Finally, fre-
quency and surface density of KIR3DS1 can be further affected
by copy number variants of KIR3DL1/S1 within the KIR locus
(Pelak etal., 2011). Increased RNA expression and percentage of
KIR3DS1+ NK cells but not KIR3DL1+ NK cells were observed
in individuals with multiple copies of KIR3DL1 alleles,suggesting
an interaction between the expression levels of these two allotypes
that will require further investigations.
Surface expression of KIR3DS1 can be detected by the
KIR3DL1/S1-speciﬁc mAb Z27 (Carr etal.,2007; O’Connor etal.,
2007; Trundley etal., 2007). In combination with the KIR3DL1-
speciﬁc mAb DX9 (Litwin etal., 1994), mAb Z27 is used to dis-
criminatecellswithregardstotheirsurfaceexpressionofKIR3DL1
or KIR3DS1.While Z27 and DX9 antibodies both stain KIR3DL1,
KIR3DS1 is not recognized by DX9, indicating that the antibod-
ies target different epitopes. In line with this, it has been shown
that Tyr200 is a determinant for DX9 recognition of KIR3DL1 but
not for Z27 (Khakoo etal., 2002). Furthermore, different amino
acid residues in position 199 of KIR3DL1 (proline) and KIR3DS1
(leucine) might contribute to the observed different staining pro-
ﬁles. KIR3DS1 displays low ﬂuorescence intensity when stained
with Z27. Whether this reﬂects a low binding afﬁnity of Z27
to KIR3DS1 or an overall low surface expression of KIR3DS1
in comparison to KIR3DL1 is unclear. In contrast, KIR3DL1
displays various expression levels depending on the respective
allotype, which can be discriminated into alleles with high (e.g.,
KIR3DL1*001) and low surface density (e.g., KIR3DL1*005), as
well as a null variant (KIR3DL1*004) that is not expressed on the
cell surface (Gardiner etal., 2001; Pando etal., 2003; Yawata etal.,
2006). Of note, similar to the KIR3DL1*004 allele that encodes
for a KIR3DL1 molecule that is not expressed on the cell surface,a
KIR3DS1null allele(KIR3DS1*049N)hasalsobeenidentiﬁed(Pas-
caletal.,2007).Acomplexdeletion/substitutionmutationinexon
4 resulting in a premature stop codon was identiﬁed as the under-
lying mechanism. A subsequent study analyzing allele frequencies
ofKIR3DS1*049N inthedifferentpopulationsworldwiderevealed
thatthisalleleisveryrare,suggestingthatKIR3DS1*049N isprob-
ablynotimportantlyinvolvedindiseaseassociationsdescribedfor
KIR3DS1 (Martin etal.,2007a).
Despite these recent advances in our understanding of the reg-
ulation of KIR expression on a single cell level, the underlying
mechanisms of how the KIR expression patterns are shaped are
still not fully understood. In general, cytokines and the presence
cognateHLAligandsmaybeinvolvedduringmaturationandedu-
cationof NKcellsthusinﬂuencingKIRexpressionpatternswithin
the NK cell population. With regards to KIR3DS1,further studies
are needed to fully understand how expression of KIR3DS1 is reg-
ulated and to determine the potential functional consequences of
increased expression.
LIGAND SPECIFICITY OF KIR3DL1 AND KIR3DS1
Classical and non-classical HLA class I molecules can serve as
natural ligands for several inhibitory and activating KIRs (Bias-
soni etal., 1995; Rajagopalan and Long, 1999; Hansasuta etal.,
2004). Moreover, crystal structures of certain KIR/peptide/HLA
complexes have clariﬁed the molecular interactions between KIR
and peptide-loaded HLA molecules (Boyington etal., 2000; Fan
etal., 2001; Vivian etal., 2011), including the KIR3DL1 and
HLA-B57 pair.
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KIR3DL1 recognizes HLA-A and -B molecules containing the
HLA-Bw4 motif (Cella etal., 1994; Gumperz etal., 1995; Stern
etal.,2008).However,KIR3DL1displaysdifferentialafﬁnitiestoits
cognate HLA class I ligands depending on the encoding KIR3DL1
allele,therespectiveHLAallele,andtheHLAclassI-presentedepi-
tope (Carr etal., 2005; Thananchai etal., 2007; Foley etal., 2008;
Fadda etal., 2011). Minor changes in the amino acid sequence
of KIR3DL1 in regions interacting with the peptide/HLA com-
plex can lead to either increased afﬁnity or complete abrogation
of binding. Two polymorphisms at position 238 (D2 domain)
and320(TM)thatdiscriminateKIR3DL1*002andKIR3DL1*007
were identiﬁed to affect the ability of HLA-Bw4 ligands to inhibit
KIR3DL1*002- and KIR3DL1*007-expressing NK leukemia cell
lines (Carr etal., 2005). Moreover, it has been shown that the dif-
ferential binding of KIR3DL1 to HLA-A*2402 in complex with
an HIV-1 peptide is mediated by dimorphic motifs in the D0 and
D1/D2 domains of KIR3DL1 (Sharma etal., 2009). Thus, single
amino acid substitutions within KIR3DL1 play a critical role in
the binding afﬁnity to HLA ligands and can provide insights into
themolecularmechanismsthatregulateKIR/HLAinteractions.In
addition,it has been shown that a single amino acid change in the
KIR2D receptors deﬁnes the ability of KIR2D receptors to recog-
nizeeitherHLA-Cgroup1or2receptors. Thissuggestsaunifying
concept of ligand speciﬁcity and afﬁnity for KIR proteins (Winter
and Long, 1997; Moesta etal.,2008).
The binding afﬁnity of KIR3DL1 to its cognate HLA class I
molecules is further dependent on the HLA class I presented
peptides. In particular, amino acid residues in position 7 and
8 of the HLA-bound peptide seem to be pivotal in either pro-
moting or abrogating binding of KIRs to their cognate HLA
class I molecules (Peruzzi etal., 1996; Mandelboim etal., 1997;
Rajagopalan and Long, 1997;Vales-Gomez etal., 1998; Hansasuta
etal., 2004; Fadda etal., 2010). In this context, it has been shown
that binding of KIR3DL1 to HLA-B57 was affected by a variety
of HIV-1-derived peptides (Fadda etal., 2011). Crystal structures
of KIR/HLA/peptide complexes conﬁrmed a direct interaction
between residues 7 and 8 of the HLA-presented peptide and KIRs
(Boyington etal., 2000; Vivian etal., 2011). Overall, amino acid
polymorphisms within KIR proteins and HLA class I-presented
epitopesrepresenttwopivotalmechanismsdeﬁningthebindingof
KIR proteins to their cognate HLA ligands. These polymorphisms
might provide NK cells with an ability to distinguish changes of
the epitope repertoire presented by HLA class I on virus-infected
and transformed cells.
Despite a high sequence homology (>95%) between KIR3DS1
andKIR3DL1(Dohringetal.,1996),directbindingof KIR3DS1to
HLA class I molecules has not been convincingly demonstrated to
date. However, several genetic studies have suggested a functional
interactionbetweenKIR3DS1andHLA-Bw4moleculesinhuman
diseases (Martin etal., 2002; Lopez-Vazquez etal., 2005). Mar-
tin etal. (2002) ﬁrst identiﬁed an association between KIR3DS1
and certain HLA-B alleles and the progression to AIDS. The com-
bined presence of KIR3DS1 and HLA-B alleles that encode an
isoleucine at position 80 (HLA-Bw4-I80) was associated with sig-
niﬁcantly slower progression to AIDS, while the absence of either
KIR3DS1 or HLA-Bw4-I80 alleles led to the loss of the observed
effect. The combined KIR3DS1/HLA-Bw4-I80 genotype was also
associated with decreased susceptibility for the development of
hepatocellularcarcinomainpatientswithchronichepatitisCvirus
(HCV; Lopez-Vazquez etal., 2005). These data implicate a poten-
tial interaction between HLA-Bw4-I80 molecules and KIR3DS1,
and suggested a functional role for KIR3DS1 in NK cell-mediated
recognition of HIV-1-infected as well as transformed cells. How-
ever, not all studies have demonstrated a synergistic protective
effect of the compounded genotype in the context of HIV-1
infection. Other groups have shown that the beneﬁcial effects of
HLA-Bw4-I80 and KIR3DS1 are independent and not linked to
each other (Barbour etal., 2007), or have observed a detrimental
effect of carriage of KIR3DS1 on progression of HIV-1 infection
(Gaudieri etal.,2005).
Basedonthesegeneticassociationsstudies,severalgroupshave
sought to assess a direct interaction of KIR3DS1 and HLA-Bw4-
I80classImolecules. Gillespieetal.(2007)usedmultipleBw4-I80
MHC class I tetramers refolded with a broad panel of HIV-1
peptide epitopes to detect tetramer binding to KIR3DS1 tran-
siently expressed on 293-T cells, while O’Connor etal. (2007)
used a luciferase reporter assay to detect activation of KIR3DS1-
transfected Jurkat cells in response to stimulation with 721.221
cells transfected with multiple HLA-Bw4 molecules. Although
these methods were successfully used to identify HLA/peptide
complexes as ligands for KIR3DL1, the same assays failed to
showanydetectableinteractionwithKIR3DS1.Anotherapproach
was chosen by Carr etal. (2007) using KIR3DS1–IgG fusion
constructs to identify binding with HLA-B*5701 transfected
721.221 cells. Again, the authors were not able to identify
HLA-Bw4-I80 molecules as a ligand for KIR3DS1. In contrast
to KIR3DL1+ NK cells, proliferation and cytotoxic capacity
of KIR3DS1+ NK cells were not affected by HLA-Bw4+ irra-
diated allogeneic EBV-B cell lines (Morvan etal., 2008, 2009).
T h eo n ee x c e p t i o ni sar e c e n ts t u d yb yLi etal. (2010) suggest-
ing interactions between KIR3DS1 and HLA-Bw4-T80 allotype
HLA-B*2705 by using surface plasmon resonance (SPR) tech-
nology. However, there were some limitations in the design of
these studies, including the lack of negative controls that demon-
strate that binding of KIR3DS1 to the HLA/peptide complex
is speciﬁc. Overall, additional studies will be needed to deter-
mine whether KIR3DS1 can bind to HLA-Bw4 molecules, and
whether these interactions depend on the HLA class I-presented
epitope.
Thesestudieswhichhaveinvestigatedtheallele-speciﬁccharac-
teristicsofKIR3DL1haveprovidedhelpfulinsightsinthepotential
molecularinteractionbetweenKIR3DS1andHLA-Bw4molecules
(see Table 1). Despite the high level of homology to KIR3DL1,
KIR3DS1 differs in at least six amino acid positions through-
out the extracellular domains, including positions 163, 166 (D1
domain), and 199 (D2 domain; Gardiner etal., 2001). Introduc-
tion of any of these KIR3DS1-speciﬁc amino acid residues into
a KIR3DL1*001 molecule as performed by Sharma etal. (2009)
led to complete abrogation of binding to HLA-A*2402, a con-
ﬁrmed ligand for KIR3DL1. In this context, Thomas etal. (2008)
identiﬁed a natural KIR3DL1 allotype (KIR3DL1*054) that shares
the same amino acid residues at position 138, 163, and 166 of
the D1 domain with KIR3DS1*013. Introduction of these sin-
gle amino acid substitutions at position 138, 163, and 166 into
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Table 1 | Effects of selected amino acid variations within KIR3DL1/S1 on antibody recognition and HLA binding.
Domain Position 3DS1a 3DL1a Effect on antibody staining and HLA bindingb Reference
D0 58 G S DX9 and Z27 binding: reductionc Sharma etal. (2009)
D0 92 M V DX9 and Z27 binding: reductionc Sharma etal. (2009)
D1 138 W G DX9 and Z27 binding: no effectc, reductionc Sharma etal. (2009), O’Connor etal. (2011)
Tetramer binding (HLA-B*5701): no effectd Vivian etal. (2011)
Tetramer binding (HLA-A*2402): reductionc O’Connor etal. (2011)
Tetramer binding (HLA-B*2705): abrogationc O’Connor etal. (2011)
D1 163 S P DX9 and Z27 binding: reductionc,n oe f f e c t c Sharma etal. (2009), O’Connor etal. (2011)
Tetramer binding (HLA-A*2402): abrogationc, reductionc Sharma etal. (2009), O’Connor etal. (2011)
Tetramer binding (HLA-B*2705): abrogationc O’Connor etal. (2011)
D1 166 R L DX9 binding: reductionc Sharma etal. (2009)
Tetramer binding (HLA-A*2402): abrogationc Sharma etal. (2009), O’Connor etal. (2011)
Tetramer binding (HLA-B*5701): reductiond Vivian etal. (2011)
Tetramer binding (HLA-B*2705): abrogationc O’Connor etal. (2011)
D2 199 L P DX9 and Z27 binding: no effectc Sharma etal. (2009)
Tetramer binding (HLA-A*2402): abrogationc Sharma etal. (2009)
Tetramer binding (HLA-B*5701): reductiond Vivian etal. (2011)
aAmino acid residue of KIR3DS1*013 and KIR3DL1*015, respectively; bTetramers folded with the following peptides: HLA-B*5701: LSSPVTKSF (self-peptide), HLA-
A*2402: RYPLTFGW (HIV nef), HLA-B*2705:TSTLQEQIGW (HIV gag); cEffect observed when aa introduced in KIR3DL1*015; dEffect observed when aa introduced
in KIR3DL1*001.
KIR3DL1*01502alsoleadtolossofrecognitionofHLA-A*2402or
HLA-B*2705 (O’Connor etal., 2011) conﬁrming the importance
of theseresidues.Moreover,thereverseintroductionof KIR3DL1-
speciﬁc residues in KIR3DS1*013 led to measurable binding of
HLA-A*2402butalsorevealedacomplexinteractionbetweendis-
tinct KIR3DS1-speciﬁc residues and HLA class I residues. While
thesubstitutionoftryptophantoglycineatposition138seemedto
besufﬁcienttoreconstituteHLAbinding,theadditionalintroduc-
tionof prolineatposition199resultedinthelossof HLAbinding.
Interestingly, the existence of one KIR3DS1 allotype (3DS1*014)
carrying glycine at position 138 has been described previously
(Crum etal., 2000; Norman etal., 2007). This potentially rep-
resents an intermediate step in the evolution of the activating
KIR3DS1 from the ancestral inhibitory KIR. The extremely low
frequency of this particular HLA-Bw4 binding KIR3DS1 allotype
might reﬂect the strong negative effect on selection in the pres-
ence of a KIR3DS1 allele with broad binding afﬁnity to HLA-Bw4
molecules.
The crucial role of these amino acid residues within KIR3DL1
and KIR3DS1 in HLA binding was also conﬁrmed by the recent
description of the crystal structure of KIR3DL1*001 in com-
plex with self-peptide-loaded HLA-B*5701 (Vivian etal., 2011).
The authors identiﬁed a “hotspot” within the D1/D2 domain
of KIR3DL1 that contains three loops (165–167, 199–201, and
278–282),which seem to be pivotal for binding to HLA-B57. This
region is altered in KIR3DS1 and might provide an explanation
for why there is no direct interaction between HLA-B*5701 and
KIR3DS1.WhethertheKIR3DS1-speciﬁcaminoacidresiduespre-
clude recognition of other HLA-Bw4-I80 molecules is unknown
and needs to be clariﬁed by additional studies.
It has been shown that binding of KIR to its cognate lig-
and is dependent on the presented peptide (Malnati etal., 1995;
Zappacosta etal.,1997; Maenaka etal., 1999; Stewart etal., 2005;
Thananchai etal.,2007) thus raising the possibility that KIR3DS1
mightbindHLA-Bw4-I80moleculesundercertaincircumstances.
KIR3DL2 recognizes HLA-A*3 and HLA-A*11 molecules only in
the presence of a small number of speciﬁc EBV-derived peptides
(Hansasuta etal., 2004). Hence, KIR3DS1 might recognize HLA-
Bw4 molecules in combination with speciﬁc peptides in a very
restricted fashion. This would prohibit recognition and killing
of self-peptide presenting normal cells and prevent autoimmune
reactions of KIR3DS1+ NK cells. In contrast, it has been shown
that stressed or virus-infected cells undergo alteration in their
presented peptide repertoire (Hickman etal., 2003; Meiring etal.,
2006). Itisconceivablethatthesecellscouldbedetectedandkilled
by NK cells via engagement of activating KIRs such as KIR3DS1.
However, the controversial discussion as to whether KIR3DS1
recognizes HLA-Bw4 molecules will continue until a direct inter-
action is proven. Thus, alternative hypotheses for effects exerted
by KIR3DS1 on the outcome of certain diseases continue to be a
topic of interest to the ﬁeld.
ROLE OF THE KIR3DS1 IN DISEASES
Several studies have identiﬁed KIR3DS1 to be associated with the
outcomeofvariousdiseases(reviewedinJamilandKhakoo,2011),
includingviralinfections,mostprominentlyHIV-1infection,cer-
tain malignancies, and auto immune diseases (see Table 2). In
particular, the role of KIR3DL1/S1 in viral infections has been
well-acceptedsincetheﬁrstdescriptionsofsigniﬁcantassociations
between the KIR3DL1/S1 gene locus and the outcome of HIV-1
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Table 2 | Selected disease associations of KIR3DS1.
Disease Association when KIR3DS1 is present
Viral infections
HIV-1 Delayed progression toAIDS in combination
with HLA-Bw4-I80 (Martin etal., 2002)
Hepatitis B virus infection Increased rate of spontaneous recovery
(Zhi-Ming etal., 2007)
H1N1 inﬂuenza A Severe pandemic inﬂuenza A infections
(Aranda-Romo etal., 2012)
Malignancies
Hepatocellular carcinoma ReducedriskincombinationwithHLA-Bw4-
I80 (Lopez-Vazquez etal., 2005)
Hodgkin’s lymphoma Reduced risk (Besson etal., 2007)
Respiratory papillomatosis Reduced risk (Bonagura etal., 2010)
Cervical neoplasia Increased risk (Carrington etal., 2005)
Other
Allogeneic HSCT Decreased progression-free survival
of patients with multiple myeloma
(Gabriel etal., 2010); decreased overall
survival in HLA-Bw4− patients (Gagne etal.,
2009); decreased acute GVHD (Venstrom
etal., 2010)
Ankylosing spondylitis (AS) Increased susceptibility for development of
AS (Lopez-Larrea etal., 2006; Diaz-Pena
etal., 2010)
infection(Martinetal.,2002,2007b).Subsequentstudiesobserved
aprotectiveeffectofthecombinedpresenceofKIR3DS1andHLA-
Bw4-I80 alleles in patients with chronic HIV-1 infection. These
ﬁndings include key determinants of progressive HIV-1 infection
such as lower viral load, slower decline of CD4+ T cell count
and delayed progression to AIDS (Martin etal., 2002; Qi etal.,
2006). In addition, in these studies it has been shown that an
increased KIR3DS1 count generated by copy number variants of
KIR3DL1/S1 was associated with a lower viral set point in the
presence of HLA-Bw4-I80 alleles (Pelak etal.,2011).
However, other observations questioned the concept of a syn-
ergistic effect of theKIR3DS1/HLA-Bw4-I80 compound genotype
onHIV-1disease,ortheprotectiveeffectofKIR3DS1onthecourse
of HIV-1 infection. A cohort study conducted by Barbour etal.
(2007)indicatedthatKIR3DS1andHLA-Bw4-I80 mightindepen-
dently exert a protective effect on the course of HIV-1 infection.
The authors showed that HIV-1-positive individuals carrying
KIR3DS1 displayed increased CD4+ T cell counts as compared
to those without KIR3DS1 and that carriage of HLA-Bw4-I80 was
associated with lower viral loads. Gaudieri etal. (2005) reported a
detrimentaleffectof theKIR3DS1allelewhichwasassociatedwith
an increased hazard ratio for AIDS disease progression.
Another complicating issue is the inconsistency of ﬁndings in
HIV-1 exposed seronegative subjects (HESN) regarding the inﬂu-
ence of KIR3DS1 on HIV-1 acquisition. Two studies described
ap r o t e c t i v er o l eo fKIR3DS1 in these particular cohorts (Boulet
etal., 2008; Tomescu etal., 2011). In contrast, two studies con-
ducted by Tomescu etal. (2010) and O’Connell etal. (2009) did
not observe an enrichment of KIR3DS1 and HLA-Bw4-I80 alleles
in HESN (Tomescu etal., 2010). This suggests that host factors
other than KIR3DS1 may be involved in the control of HIV-1
infection.
Nevertheless, functional studies in KIR3DS1+ NK cells, in
particular in acute HIV-1 infection, have provided some indica-
tions for an interaction of KIR3DS1 and HLA-Bw4-I80. Results
obtained by Alter etal. (2009) demonstrated an expansion of
KIR3DS1+ NK cells in acute HIV-1 infection, however only in
individualsthatalsoencodedforHLA-Bw4-I80alleles.Inaddition,
HLA-Bw4-I80-dependentkillingofHIV-1infectedtargetcellsand
inhibition of viral replication by KIR3DS1+ NK cells has been
described (Alter etal., 2007). Although a subsequent study con-
ductedbyLongetal.(2008)observedincreasedIFN-yandCD107a
expression of NK cells in KIR3DS1+ individuals with early HIV-
1 infection, this ﬁnding was independent of the joint carriage of
HLA-Bw4-I80.However,theauthorsdidobservehigherIFN-yand
CD107aexpressioninindividualsencodingforbothKIR3DS1and
HLA-Bw4 alleles, in particular in the presence of the B*58 alleles,
and the lack of detecting a statistical signiﬁcance for higher NK
cell activity in KIR3DS1/HLA-Bw4-I80+ individuals might have
beenaconsequenceofthesmallsamplesize.Inaddition,increased
frequency and antiviral capacity against HIV-1 of KIR3DS1+ NK
cells were recently described in individuals encoding for multiple
copies of KIR3DL1 (Pelak etal., 2011). The results from the study
by Pelak etal. (2011) indicate that KIR3DL1-dependent licensing
ofNKcellsmightbeinvolvedinshapingastrongantiviralresponse
ofKIR3DS1+NKcells.HigherresponsivenessoflicensedNKcells
might therefore serve as one potential underlying mechanism for
the protective effect of the combined presence of KIR3DL1 and its
cognateHLAligandsinchronicHIV-1infection(Kimetal.,2008).
Overall, although a beneﬁcial effect of KIR3DS1 in the context
of HIV-1 infection has been observed in some in vivo and in vitro,
it remains unknown whether this effect is mediated by KIR3DS1
itself or other genes in linkage disequilibrium with KIR3DS1.
Furthermore, it is not clear whether changes in KIR3DL1 copy
numbers in KIR3DS1+ individuals are responsible for this pro-
tective effect or whether this is dependent on the simultaneous
presence of HLA-Bw4-I80.
The role of KIR3DS1 has also been investigated in other viral
infections such as human T-cell leukemia virus type 1 (HTLV-1),
H1N1 inﬂuenza A, and hepatitis B virus infection (HBV). While
noevidencefortheparticipationofKIR3DS1incontrolofHTLV-1
infection was found (O’Connor etal.,2012),carriage of KIR3DS1
and other haplotype B containing KIRs was associated with severe
pandemic inﬂuenza A (H1N1) 2009 infections (Aranda-Romo
etal., 2012). Frequencies of KIR3DS1 as well as KIR2DS1 and
KIR2DL5 were furthermore increased in a group of patients who
spontaneouslyrecoveredfromHBVcomparedtoindividualswith
chronicHBVinfectionorhealthycontrols(Zhi-Mingetal.,2007).
Because of the close proximity of the genes within the KIR locus
and the resulting strong linkage disequilibrium with neighbor-
ing genes, it remains unclear whether the observed effects are
due to a speciﬁc KIR. Furthermore, the mechanisms underlying a
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potential protective effect of speciﬁc KIR genotypes remain to be
elucidated.
Aside from their important role in controlling viral infections,
NK cells can also mediate antitumor immunity (reviewed in Wu
and Lanier, 2003). Association studies investigating the impact
of KIR/HLA haplotypes in selected malignancies have identiﬁed
protective as well as unfavorable KIR/HLA haplotypes, includ-
ing some comprising KIR3DS1 (Arnheim etal., 2005; Purdy and
Campbell, 2009; Karabon etal., 2011). A protective effect of
KIR3DS1 in combination with HLA class I molecules expressing
the HLA-Bw4-I80 epitope in hepatocellular carcinoma has been
observed in patients with chronic HCV infection (Lopez-Vazquez
etal., 2005). The underlying mechanism of this protective geno-
type is not known. It is possible that transformed cells in the
HCV-infected liver encode for a KIR3DS1 ligand and are directly
recognized and killed by KIR3DS1+ NK cells. A decreased risk
for the development of Hodgkin’s lymphoma (HL), a common
lymphoma in young adults, was also identiﬁed in individuals car-
ryingKIR3DS1infamilialstudywith90casesand255ﬁrst-degree
relatives (Besson etal., 2007). In addition, absence of KIR3DS1
and KIR2DS1, which display strong linkage disequilibrium, was
associated with more frequent occurrence of respiratory papil-
lomatosis (RRP), a rare disease of the larynx and upper airway
caused by human papillomaviruses (HPV)-6/11 (Bonagura etal.,
2010). Of note, all three malignancies described above are caused
or at least promoted by viral infections, indicating a potential
role of KIR3DS1 in the control of the underlying viral infections.
Thus, it is possible that the protective role of KIR3DS1 is due
to the recognition of virus-infected cells by KIR3DS1+ NK cells
similar to other viral infections. In contrast, some studies have
described a detrimental effect of KIR3DS1 in cervical cancer and
on the outcome of unrelated hematopoietic stem cell transplan-
tation (HSCT). An increased susceptibility to the development of
cervical neoplasia in patients carrying KIR3DS1 was identiﬁed by
Carrington etal. (2005). Of note, similar to the above mentioned
RRP,cervical neoplasia is also a HPV-associated disease. However,
in this case the presence of KIR3DS1+ NK cells might be detri-
mental due to incomplete viral control and chronic inﬂammation
that might facilitate the development of cancer.
In a multivariate analysis Gabriel etal. (2010) showed that
progression-free survival of patients with multiple myeloma after
autologous stem cell transplantation was signiﬁcantly decreased
in patients carrying the KIR3DS1 gene. Furthermore, Gagne etal.
(2009) observed the lowest overall survival in HLA-Bw4− patients
withmyelogenousdiseasesreceivingKIR3DL1+/KIR3DS1+donor
NK cells during HSCT. In contrast, a beneﬁcial effect of KIR3DS1
in the context of T cell-depleted HSCT has also been observed,
showing a protective effect of donor KIR haplotype B against
leukemic relapse and improved disease-free survival in patients
undergoingHSCT(Verheydenetal.,2005;Marcenaroetal.,2011).
Venstrom etal. (2010) furthermore showed that transplantation
of hematopoietic stem cells from KIR3DS1+ donors was asso-
ciated with decreased acute graft-versus-host disease (GVHD).
Although the underlying mechanism of the observed effects are
not understood, the above studies indicate a potential role of
NK cell licensing in the setting of HSCT as the HLA and KIR
haplotypes of the donor deﬁne NK cell responses in the new host.
Finally, with regards to autoimmune diseases, a growing num-
ber of studies suggest a role for NK cells in disease pathogenesis.
In particular, KIR3DS1 has been associated with the development
and progression of ankylosing spondylitis (AS; reviewed in Diaz-
Pena etal., 2009 and Azuz-Lieberman etal., 2005). AS represents
a prototypic subtype of a group of various related diseases sum-
marized as spondyloarthritis (reviewed in Dougados and Baeten,
2011). The characteristic symptoms include chronic inﬂamma-
tion of the joints and ligaments of the spinal bones that can be
triggered by mechanical or bacterial stress. Although the exact
underlying pathology remains unknown, genetic predisposition
accounts for 80–90% of the cases, and include the presence of
HLA-B27 allotypes as a major risk factor (Thomas and Brown,
2010). Several studies observed enrichment for KIR3DS1 in HLA-
B27+ patients with AS (Lopez-Larrea etal., 2006; Diaz-Pena
etal., 2010), while KIR3DL1 was found to be underrepresented
in patients with AS as compared to HLA-B27+ healthy controls
(Mousavietal.,2010;Wangetal.,2012).Withregardstotheligand
speciﬁcityof KIR3DS1,functionalstudiesinvestigatingapotential
interaction of KIR3DS1 and HLA-B27 in the context of AS have
not been conducted. Moreover, whether the underlying mecha-
nism of the increased susceptibility to the development of AS in
KIR3DS1+ individuals involves a differential activation threshold
of KIR3DS1+ NK or CD8+ T cells is not known. These data
also indicate that the presence of KIR3DS1 is a more important
factor in the development of AS than the absence of protective
KIR3DL1 allotypes. However, it should be noted that other stud-
iesneitherobservedanysigniﬁcantinvolvementof KIR3DL1/S1in
the outcome of AS (Harvey etal.,2009),nor identiﬁed other com-
pound KIR genes and HLA allotypes linked to the development
and progression of AS (Diaz-Pena etal., 2008; Jiao etal., 2010;
Tajik etal.,2011).
Taken together, these studies suggest that KIR3DS1 might not
only play a role in the outcome of viral infections, but also in
malignancies,the outcome after HSCT,and auto immune disease.
Additional functional studies of NK cells are required in these
diseasesettingstodeterminewhetherKIR3DS1exertsitsprotective
or detrimental effects through modulation of NK cell function,or
by alternative mechanisms.
CONCLUDING REMARKS
An accumulating number of studies have demonstrated the
inﬂuence of KIR3DS1 on the outcome of various human dis-
eases. Furthermore, the ubiquitous presence of KIR3DS1 within
human populations suggests an evolutionary pressure to main-
tain this activating KIR. The lack of a deﬁned ligand for
KIR3DS1 has signiﬁcantly hampered functional studies to deter-
mine the mechanisms underlying KIR3DS1-associated protection
from disease, but might also suggest a restricted engagement of
KIR3DS1 to prevent killing of normal cells and thus damage of
the host.
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